Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with systemic sclerosis (a condition where the immune system causes hardening and tightening of the skin and connective tissues) based on the 2013 classification guidelines set by two major rheumatology organisations
- People whose lungs have been affected by a related condition called interstitial lung disease, which has been confirmed by a specialised type of chest scan called an HRCT (a detailed CT scan of the lungs)
Who may not be able to join:
- People whose lung disease appears to be caused by something other than systemic sclerosis — for example, silicosis (lung damage from silica dust), sarcoidosis (an inflammatory condition), lung cancer, or other significant lung problems
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paul Decker, MD, Central Hospital, Nancy, France
Phone: +33383157240
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
HRCT scan variables
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.